Shares of Beta Bionics Inc. (NASDAQ: BBNX) surged 14.87% in pre-market trading on Wednesday, October 29, 2025, following the company's impressive third-quarter earnings report and increased full-year guidance released after market close on Tuesday.
The medical device company, known for its iLet Bionic Pancreas System, reported a narrower-than-expected loss of $0.33 per share for Q3, significantly beating analyst estimates of a $0.44 loss. Revenue for the quarter came in at $27.3 million, surpassing expectations of $23.97 million and marking a robust 63.14% increase from the same period last year. The strong performance was driven by impressive growth across both its Durable Medical Equipment (DME) and Pharmacy Benefit Plan (PBP) sales channels.
In light of these results, Beta Bionics raised its full-year 2025 revenue guidance to over $96.5 million, up from the previous range of $88 million to $93 million. The company also increased its estimated gross margin forecast for the year to 54-55%, up from the prior range of 52-55%. Adding to the positive momentum, Beta Bionics announced it received Special 510(k) clearance from the FDA on September 29, 2025, for updates to its iLet device, further strengthening its market position in the diabetes management space.
Analysts have responded positively to the news, with Leerink Partners raising their price target for BBNX from $28 to $33. The combination of strong financial performance, raised guidance, and product advancements has fueled investor enthusiasm, resulting in the significant pre-market stock price surge.
Comments